RxDoctor Payments DataLook up a doctor →

Theodore Daly, MD

Dermatology · Garden City, NYNPI 1518965441

Payments from drug & device makers

$490,050in general payments, 2019–2025

Across 1,107 payments — averaging $442.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$128K
  • Lilly USA, LLC$120K
  • Amgen$113K
  • Boehringer Ingelheim$40K
  • Bristol Myers Squibb$21K
  • AbbVie$19K
  • plus $49K from 30 others

What the payments were for

  • Consulting fees$49,90910%
  • Speaking & faculty fees$371,59577%
  • Travel & lodging$32,5627%
  • Food & beverage$24,7255%
  • Education$1,2420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$490,050 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$1,545,187
Medicare patients
1,217
Services billed
23,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate55$168,751
OtezlaApremilast24$148,253
Dupixent PenDupilumab19$76,262
JubliaEfinaconazole27$37,285
ZoryveRoflumilast33$29,264
Tacrolimus70$13,159
Minoxidil822$8,603
Dutasteride198$6,167
Clobetasol Propionate114$5,260
Spironolactone435$5,031
Tretinoin70$4,371
Halobetasol Propionate77$4,048
Acitretin13$4,003
Tretinoin MicrosphereTretinoin Microspheres11$3,697
Azelaic Acid18$3,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$793$168,75155 claims
AmgenOtezla$113,393$148,25324 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$1,911$37,28527 claims
Arcutis Biotherapeutics, Inc.Zoryve$4,466$29,26433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →